Dark Matter | CEO Blog

Discovering a New World of RNA-Targeted Medicines

February 27th, 2017 | Arrakis Therapeutics

So here we are. Nearly two years in the making, much of it focused, fastidious work by founder Russ Petter (of whom much more below), capped by an exhilarating and exhausting sprint to the finish by an outstanding team, Arrakis Therapeutics has now lifted off. Today we announced a $38M Series A financing led by […]

Escaping the Gravitational Pull of “Druggability”

February 22nd, 2017 | Arrakis Therapeutics

Most old-timers in drug discovery will agree on one thing: It never gets easier. Sure, maybe we learn a little from our mistakes along the way and the toolkit gets steadily flashier. But the easy targets, if ever they were truly easy ones, are long gone. We are left with either inscrutable biology or, even […]

Back to Top